The highly publicized Lindsay Clancy case has focused attention on the severe consequences that can arise when postpartum mental illness is not detected or effectively treated. Beyond legal questions about individual culpability, the case underscores broader clinical realities: clinicians and researchers have limited tools to identify women at highest risk, to predict who will respond to which treatments, and to detect rapid deterioration before catastrophe. The authors, reproductive psychiatrists and neuroscientists who did not treat Clancy, argue that these limitations reflect the current state of postpartum psychiatric care rather than failures of compassion.
Postpartum depression is common, affecting roughly 1 in 7 to 1 in 8 women after childbirth, yet diagnosis remains anchored in patient self-report and clinical interviews. Screening questionnaires are widely used and provide value, but they are imperfect. Some women minimize or withhold symptoms because of shame, fear of losing custody, or concern about stigma. Others present with atypical signs that do not align neatly with diagnostic criteria. Unlike many other medical specialties, postpartum psychiatry lacks routine objective laboratory tests, imaging, or genetic assays to confirm or refine diagnoses, leaving clinicians to make high-stakes decisions on the basis of subjective information.
By contrast with postpartum depression, postpartum psychosis is rare and frequently follows a fluctuating course: women may appear relatively well at one point and severely ill the next. This waxing-and-waning pattern complicates timely recognition. Because severe illness can escalate quickly, opportunities for prevention may be missed by the time psychosis is obvious, reducing windows for effective intervention and increasing the risk of tragic outcomes.
Standard antidepressants, including selective serotonin reuptake inhibitors (SSRIs), are commonly used because they are familiar, accessible, and generally well tolerated. However, they often require weeks to achieve full effect, do not help all patients, and may be contraindicated depending on the specific diagnosis (for example, in bipolar-spectrum presentations). The need for prolonged treatment trials and the absence of reliable predictors of response mean many patients undergo a period of ineffective therapy before benefit, if any, emerges.
Recent pharmacologic advances have produced more rapid-acting treatments that can shorten the time to symptom improvement for some patients. While these developments offer hope, they also expose systemic limitations: high cost and limited availability create inequities in access, and clinicians still lack dependable methods to predict which individual patient will benefit from a given therapy. As a result, therapeutic selection often remains a trial-and-error process.
Postpartum depression, postpartum psychosis, anxiety disorders, and bipolar-spectrum illness can present with overlapping features, further complicating differential diagnosis. Even expert clinicians may find it difficult to distinguish among these conditions in the absence of objective biomarkers. The overlap matters because treatment strategies and risks differ across diagnoses, and an inappropriate or delayed choice of treatment can worsen outcomes.
The authors advocate prioritizing research into predictive biomarkers that could provide objective information during pregnancy and the postpartum period. Potential applications include identifying which women are at high risk for severe postpartum depression or psychosis, predicting who is likely to respond to a given therapy, determining who needs more intensive monitoring, and flagging patients at imminent risk of psychiatric emergency. Early research has identified candidate signals, including epigenetic signatures and other biological markers that may forecast risk before symptoms appear. If validated and implemented equitably, such tools could improve prevention, personalize treatment selection, and reduce reliance on prolonged trial-and-error approaches.
The broader lesson drawn from the case is that gaps in postpartum mental health care stem less from a lack of compassion and more from limited precision in diagnosis and treatment. Better objective tools and targeted therapies would not eliminate all tragedies, but they could substantially improve outcomes for many women and families.
This commentary was written by Jamie Maguire, Ph.D., Lauren M. Osborne, M.D., and Jennifer Payne, M.D., who declare they did not treat Lindsay Clancy. One author, Jamie Maguire, discloses she is a named inventor on a pending U.S. patent application related to a biomarker approach for psychiatry; the application is pending and no patent has been granted, and she reports no personal financial benefit from the patent. The authors call for greater investment in research on predictive biomarkers and precision approaches for postpartum psychiatric illness.